Interleukin 6 News and Research

RSS

Interleukin-6 (IL-6) is a protein that in humans is encoded by the "IL6" gene. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation.

PAH role proposed for left heart failure biomarker

Levels of galectin-3 are elevated in patients with pulmonary arterial hypertension and correlate with disease severity, research shows.

10 Mar 2016

HIV-positive individuals in Africa with certain genetic variant have lower chance of developing TB

In the first known discovery of its kind, a Case Western Reserve University School of Medicine-led team has found that HIV patients in Africa with a certain genetic variant have a 63-percent lower chance of developing tuberculosis than HIV patients without the genetic variant.

10 Mar 2016

Metabolic syndrome treatment benefits MS patients

Oral antidiabetic medications have beneficial anti-inflammatory effects in patients with multiple sclerosis and metabolic syndrome, providing support for a link between metabolism and autoimmunity, researchers report.

9 Mar 2016

Protein p62 acts as molecular brake to keep inflammation in check, avoid collateral damage

Inflammation is a Catch-22: the body needs it to eliminate invasive organisms and foreign irritants, but excessive inflammation can harm healthy cells, contributing to aging and sometimes leading to organ failure and death. Researchers at University of California, San Diego School of Medicine have discovered that a protein known as p62 acts as a molecular brake to keep inflammation in check and avoid collateral damage.

26 Feb 2016

Study provides window into the brain changes that link mindfulness meditation with health-related benefits

Over the past decade, mindfulness meditation has been shown to improve a broad range of health and disease outcomes, such as slowing HIV progression and improving healthy aging. Yet, little is known about the brain changes that produce these beneficial health effects.

5 Feb 2016

Certain viral infections during pregnancy could cause behavioral changes in offspring

A study published in the journal Science found that activation in pregnant mice of a particular immune response, similar to what may occur with certain viral infections during pregnancy, alters the brain structure of the mouse offspring and causes behavioral changes, reminiscent of those observed in humans with autism spectrum disorder (ASD).

30 Jan 2016

Immunotherapy could be the future of cancer treatments

For decades most cancers have been treated with the standard of care treatments which typically include surgery, radiation and/or chemotherapy. Now there is talk that immunotherapy represents "the future of cancer treatments."

21 Jan 2016

Study provides evidence for use of inherited genetic markers to improve melanoma prognostication

Melanoma is the most dangerous and lethal form of skin cancer. But just how long will a patient survive following the removal of a melanoma tumor? A more definitive answer to that question could come from new studies at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center. Researchers there have discovered an inherited genetic marker that might provide clinicians with a personalized tool to gauge an individual's survival and determine which patients require closer monitoring in the years following surgery.

21 Jan 2016

TG4010 vaccine promising in advanced NSCLC

Addition of the TG4010 vaccine to first-line chemotherapy improves outcomes in patients with advanced non-small-cell lung cancer, show the results of a placebo controlled trial.

19 Jan 2016

UT Southwestern pediatric researchers identify key trigger of neonatal lung disease

Pediatric researchers at UT Southwestern Medical Center have identified a key component of the pathogenesis of bronchopulmonary dysplasia (BPD), a devastating and sometimes fatal lung disease that affects premature infants. Their findings clarify what prompts the inflammatory response that results in BPD, which previously had been unclear.

18 Jan 2016

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

17 Jan 2016

Virginia Tech scientists find potential way to influence memory formation in the immune system

Scientists at the Virginia Tech Carilion Research Institute have found a potential way to influence long-term memory formation in the immune system. The researchers published their results today in Nature Communications.

11 Jan 2016

New, personalized approach to detecting low back pain

Scientists at The Feinstein Institute for Medical Research have discovered a new, personalized approach to diagnosing low back pain. The findings from a clinical study show that serum levels of the proinflammatory cytokine interleukin-6 (IL-6) vary in individuals with lumbar intervertebral disc disease and that biochemical profiling of circulating cytokines may assist in refining personalized diagnoses of disc diseases.

8 Jan 2016

Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

Rani Therapeutics announced today that it has entered into a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, to evaluate Rani's novel oral drug delivery platform. The companies have agreed to conduct feasibility studies over the next two years, in which Rani will test select biologic molecules in the area of metabolic disease to evaluate the oral delivery of these molecules.

6 Jan 2016

New footage shows how AIDS vaccine candidate recruits immune cells to destroy infected cells

Using innovative technology, scientists from the Institut Pasteur and Inserm have filmed in vivo the process by which an AIDS vaccine candidate, developed by the French Vaccine Research Institute and the ANRS, triggers the immune response.

23 Dec 2015

Feeling sad can alter levels of inflammatory proteins linked to increased risk of comorbid diseases

Feeling sad can alter levels of stress-related opioids in the brain and increase levels of inflammatory proteins in the blood that are linked to increased risk of comorbid diseases including heart disease, stroke and metabolic syndrome, according to a study by researchers at The University of Texas Health Science Center at Houston.

17 Dec 2015

NEK7 enzyme acts as on-off switch in innate immune system

UT Southwestern Medical Center and California researchers today provide the first report that an enzyme previously known solely for its role in cell division also acts as an on-off switch in the innate immune system -- the body's first defense against infection.

8 Dec 2015

Researchers reveal new technique to grow human hepatocytes in the laboratory

In new research appearing in the prestigious journal Nature Biotechnology, an international research team led by The Hebrew University of Jerusalem describes a new technique for growing human hepatocytes in the laboratory. This groundbreaking development could help advance a variety of liver-related research and applications, from studying drug toxicity to creating bio-artificial liver support for patients awaiting transplantations.

27 Nov 2015

Researchers begin landmark clinical study to restore normal insulin secretion in people with type 1 diabetes

Investigators at Montreal's Lady Davis Institute at the Jewish General Hospital and McGill University Health Centre have announced the start of a landmark clinical study aimed at restoring normal insulin secretion in people with longstanding type 1 diabetes.

26 Nov 2015

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

Novartis announced today that the European Commission has approved Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS, this is the first new treatment advance in 16 years since the development of the current standard of care, anti-tumor necrosis factor (anti-TNF) therapy.

25 Nov 2015